In subsequent clinical trials, it was found that TLR-4, NANOG, and their downstream targets Yes-associated protein 1 (YAP1) and insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) expression were significantly correlated with HCC patient prognosis [52]. This evidence concerns the gene YAP1 and hepatocellular carcinoma.